Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
Summary
MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing...
Description
MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source